相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
- 库存:
99
- 供应商:
爱必信(上海)生物科技有限公司
- CAS号:
1020172-07-9
- 规格:
5mg/50mg/10mg
| 规格: | 5mg | 产品价格: | ¥970.0 |
|---|---|---|---|
| 规格: | 50mg | 产品价格: | ¥6186.0 |
| 规格: | 10mg | 产品价格: | ¥1698.0 |
| 公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:DCC-2036 (Rebastinib) 产品别名:见爱必信官网 英文别名:DCC-2036 (Rebastinib) 靶点:Bcr-Abl CAS:1020172-07-9 纯度:>98% 外观:见爱必信官网 保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. 描述: DCC-2036 (Rebastinib)是一种Bcr-Abl抑制剂,作用于Abl1(WT)和Abl1(T315I),IC50分别为0.8 nM和4 nM,也抑制SRC, LYN, FGR, HCK, KDR, FLT3,和Tie-2,对c-Kit具有低的抑制活性。DCC-2036有效抑制纯化的未磷酸化(u-ABL1native)和磷酸化 (p-ABL1native) ABL1, 未磷酸化和磷酸化突变型ABL1T315I, 及激活环突变ABL1H396P,这种作用为非ATP竞争性的,IC50分别为0.8 nM, 2 nM, 1.4 nM, 5 nM, 和 4 nM。而且, DCC-2036也抑制SRC家族激酶SRC, LYN, FGR, 和 HCK, 和受体 TKs KDR, FLT3, 和TIE2,IC50分别为34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM 和6 nM。DCC-2036作用于表达野生型或突变型BCR-ABL1的Ba/F3细胞,具有抗增殖活性,IC50为 2 nM到150 nM。 溶解性:Ethanol :13 mg/mL (23.5 mM) DMSO :103 mg/mL (186.1 mM) 体外研究: DCC-2036 shows the potent inhibitory activities against purified native Abl1 in unphosphorylated (u-Abl1native) and phosphorylated (p-Abl1native) forms, unphosphorylated and phosphorylated gatekeeper mutant Abl1T315I, and the activation loop mutant Abl1H396P in a non-ATP-competitive manner with IC50 of 0.8 nM, 2 nM, 1.4 nM, 5 nM, and 4 nM, respectively. Moreover, DCC-2036 also inhibits the Src family kinases Src, LYN, FGR, and HCK, and the receptor TKs KDR, FLT3, and TIE2 with IC50 of 34 nM, 29 nM, 38 nM, 40 nM, 4 nM, 2 nM and 6 nM, respectively. DCC-2036 shows the anti-proliferative activities against Ba/F3 cells expressing native or mutant Bcr-Abl1 with IC50 ranging from 2 nM to 150 nM. In addition, DCC-2036 also inhibits proliferation of the Ph+ cell line K562 (IC50 5.5 nM), and induces apoptosis in both Bcr-Abl1-expressing Ba/F3 and K562 cells potently. A recent study shows that DCC-2036 shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines. 体内研究:In a mouse allograft model bearing Ba/F3-Bcr-Abl1T315I leukemia cells, DCC-2036 treatment by oral gavage at 100 mg/kg once daily effectively inhibits Bcr-Abl1 signaling and significantly prolongs mouse survival.
产品信息订购:
absin,您身边的科研百宝箱 |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验7Az/y1EevzuWQnfVqCX4LfP78GTNnzcKM6dNRuHDhBLdPCw0eP3qEzh06IsyRLuyXt/jKU1ZRgaqqKtTU1aGpqQEtrSzIkiULtLWzIZeODgoVKgQTExOUKl0axYoVk+qmhTUpYg6fbTZirXDpUVajpL76MG07lo5IhqJRXmFFGiZ8+MHjkwuU1OiSLBi/hbWpUjC83dzxO7gINERVldwwm38O19udxrHjtrh6/RZOWd2lx1JAswS
技术资料暂无技术资料 索取技术资料




![8-[4-(Aminoethyl Methanethiosulfonyl)phenyl] Bodipy](https://img1.dxycdn.com/2022/1124/352/2842169574477474853-14.jpg!wh200)



